Media headlines about Daxor (NYSE:DXR) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Daxor earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.5773614090466 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Separately, TheStreet cut shares of Daxor from a “c-” rating to a “d+” rating in a research report on Friday, April 28th.

Shares of Daxor (DXR) opened at 6.1648 on Wednesday. The stock has a market cap of $23.41 million and a PE ratio of 16.0961. Daxor has a 52-week low of $5.76 and a 52-week high of $9.80. The stock’s 50 day moving average is $6.13 and its 200 day moving average is $7.14.

COPYRIGHT VIOLATION WARNING: This story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at

Daxor Company Profile

Daxor Corporation is an investment company with medical instrumentation and biotechnology operations. The Company engages in the short selling of stock. The Company maintains a diversified securities portfolio, which consists primarily of the common and preferred stocks of electric utility companies.

Insider Buying and Selling by Quarter for Daxor (NYSE:DXR)

Receive News & Stock Ratings for Daxor Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daxor Co. and related stocks with our FREE daily email newsletter.